- Johnson & Johnson's (JNJ, Financial) Phase 3 Vivacity-MG3 study shows promising results for nipocalimab in treating generalized myasthenia gravis.
- Analyst forecasts indicate a potential upside of up to 17.67% in stock price.
- GuruFocus estimates suggest an even greater potential upside of 29.04%.
Johnson & Johnson (JNJ) has announced encouraging findings from its Phase 3 Vivacity-MG3 study and the subsequent open-label extension. These results underscore the long-term efficacy of nipocalimab in managing generalized myasthenia gravis, with patients showing marked improvements in MG-ADL and QMG scores. The findings highlight significant enhancements in muscle strength and a reduction in symptom severity.
Wall Street Analysts' Insights
Wall Street analysts have set a variety of one-year price targets for Johnson & Johnson (JNJ, Financial). Currently, the average target price stands at $171.56, with estimates ranging from a high of $190.00 to a low of $150.00. This average target suggests a 17.67% upside potential from the stock's current price of $145.80. For an in-depth analysis, visit the Johnson & Johnson (JNJ) Forecast page.
In terms of brokerage recommendations, Johnson & Johnson (JNJ, Financial) receives an average rating of 2.3 from 26 firms, categorizing it as "Outperform." This rating system uses a scale from 1 to 5, where 1 represents a Strong Buy and 5 indicates a Sell recommendation.
GuruFocus Valuation Estimates
According to GuruFocus estimates, the projected GF Value for Johnson & Johnson (JNJ, Financial) in one year is $188.13. This projection points to a potential 29.04% upside from the current price of $145.7955. The GF Value is GuruFocus' assessment of the stock's fair market value, calculated based on historical trading multiples, previous business growth, and future performance forecasts. For more comprehensive data, refer to the Johnson & Johnson (JNJ) Summary page.
